Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr-Reddy’s-Laboratories"

11 News Found

Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority
News | April 07, 2025

Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority

Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws


JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
News | July 01, 2022

JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories

The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores


Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push
News | June 15, 2026

Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push

Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing


Indian Immunologicals clocks all-time high revenue of Rs 1,586 crore in FY26
Biopharma | April 27, 2026

Indian Immunologicals clocks all-time high revenue of Rs 1,586 crore in FY26

Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%


Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition
News | February 19, 2026

Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition

The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India


Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
News | December 09, 2025

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Industry seeks favourable policy for India to move up the pharma value chain globally
Policy | February 27, 2022

Industry seeks favourable policy for India to move up the pharma value chain globally

N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry


DCGI approves anti-COVID drug developed by DRDO
Policy | May 10, 2021

DCGI approves anti-COVID drug developed by DRDO

The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production